Polymorphisms in the 5α-Reductase Type 2 Gene and Response to Finasteride Treatment in BPH
April 2006
in “
The Journal of Urology
”
New to Finasteride? There is a guide in the encyclopedia. Read the guide → Studysummary This study investigates the potential influence of genetic variations in the 5α-reductase type 2 gene on the effectiveness of finasteride treatment for benign prostatic hyperplasia, but it reports no new clinical results.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The study investigated the relationship between polymorphisms in the 5α-reductase type 2 gene and the response to finasteride treatment in patients with benign prostatic hyperplasia (BPH). The research aimed to determine if genetic variations could predict the effectiveness of finasteride, a common treatment for BPH. The findings suggested that certain polymorphisms in the gene might influence the therapeutic outcomes of finasteride, potentially guiding personalized treatment strategies for BPH patients. However, the document did not specify the number of participants involved in the study, which is crucial for assessing the strength of the findings.
